Autologous haematopoietic stem cell transplantation in standard-risk T-cell acute lymphoblastic leukaemia/lymphoma with negative residual disease status
Anna Kopinska, Anna Koclega, Adrianna Spałek, Patrycja Zielinska, Grzegorz Helbig · 2026
Read Autologous haematopoietic stem cell transplantation in standard-risk T-cell acute lymphoblastic leukaemia/lymphoma with negative residual disease status by Anna Kopinska, Anna Koclega, Adrianna Spałek, Patrycja Zielinska, Grzegorz Helbig (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13426173.txt.
Description
Anna Kopinska and colleagues evaluated autologous stem cell transplantation for standard-risk T-cell acute lymphoblastic leukemia and lymphoma in a 2026 single-centre retrospective analysis. These rare, aggressive blood cancers relapse often despite intensive chemotherapy, and donor transplantation, while standard for high-risk disease, carries heavy toxicity. The role of using a patient's own stem cells after deep remission remained controversial even with sensitive residual disease testing.
Their cohort covers adults with standard-risk disease who reached complete remission with negative measurable residual disease before autologous consolidation. Outcomes data help hematologists judge whether the gentler transplant can hold remission without donor risks. Own cells spare sick men and women the graft risks that donor cells bring, so a win here would widen who can take this kind of care.
Catalog record
| CREATOR | Anna Kopinska, Anna Koclega, Adrianna Spałek, Patrycja Zielinska, Grzegorz Helbig |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12443 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |